KURA - NASDAQ
Kura Oncology, Inc.
$8.65
-3.5%Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
At a Glance
Live SnapshotKura Oncology, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Kura Oncology, Inc. Income Statement
KURA • NASDAQ
| Kura Oncology, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||
67.5M | 53.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||||||||
(57K) | (0.0) | (849K) | (0.0) | (0.0) | (194K) | (0.0) | (10K) | (30K) | (31K) | (20K) | (23.9K) | (22.7K) | (22.3K) | (23.4K) | (20.5K) | (19.2K) | (0.0) | |
67.4M | 53.9M | -849K | 0.0 | 0.0 | -194K | 0.0 | -10K | -30K | -31K | -20K | -23.9K | -22.7K | -22.3K | -23.4K | -20.5K | -19.2K | 0.0 | |
OPERATING INCOME | ||||||||||||||||||
(371.1M) | (247.1M) | (165M) | (139.9M) | (131.3M) | (91.7M) | (67.5M) | (62.9M) | (36.1M) | (28.4M) | (23.9M) | (10.9M) | (22.3K) | (23.4K) | (20.5K) | (20.5K) | (19.2K) | -33.6K | |
(120M) | (77.1M) | (50.6M) | (47.1M) | (46.5M) | (31.3M) | (19.7M) | (16.1M) | (9.7M) | (8M) | (6.1M) | (3.8M) | (22.3K) | (23.4K) | (20.5K) | (20.5K) | (19.2K) | (0.0) | |
(251.1M) | (170M) | (115.2M) | (92.8M) | (84.7M) | (60.4M) | (47.8M) | (46.8M) | (26.4M) | (20.4M) | (17.8M) | (8M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-303.6M | -193.2M | -165.8M | -139.9M | -131.3M | -91.9M | -67.5M | -62.9M | -36.1M | -28.4M | -23.9M | -11.8M | -22.3K | -23.4K | -20.5K | -41K | -38.3K | -33.6K | |
PRE-TAX INCOME | ||||||||||||||||||
(1.5M) | (1.6M) | (1.5M) | (229K) | (414K) | (578K) | (580K) | (970K) | (888K) | (577K) | (88K) | (5.9K) | (5K) | (3.6K) | (1.9K) | (1.9K) | (838.0) | (0.0) | |
25.3M | 21.2M | 13.2M | 4M | 792K | 2.2M | 4.1M | 2.2M | -137K | -78K | 40K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | -849K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (2M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -33.6K | |
25.3M | 21.2M | 13.2M | 4M | 792K | 2.3M | 4.4M | 2.6M | 943K | 807K | 972K | 879K | 16.9K | 17.4K | 19.8K | 18.6K | 18.3K | 0.0 | |
-278.4M | -172M | -152.6M | -135.8M | -130.5M | -89.6M | -63.1M | -60.4M | -35.4M | -27.6M | -22.6M | -11M | -27.3K | -27K | -22.4K | -22.4K | -20K | -33.6K | |
NET INCOME | ||||||||||||||||||
(297K) | (2M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -30K | -31K | -20K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-278.7M | -174M | -152.6M | -135.8M | -130.5M | -89.6M | -63.1M | -60.4M | -35.4M | -27.6M | -22.6M | -11M | -27.3K | -27K | -22.4K | -22.4K | -20K | -33.6K |
SEC Filings
KURA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 10, 2026 | June 04, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 29, 2026 | January 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 11, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 02, 2025 | December 02, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 |
Related Guides
Continue your KURA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.